Published in J Biol Chem on January 30, 2003
The association of Shiga-like toxin with detergent-resistant membranes is modulated by glucosylceramide and is an essential requirement in the endoplasmic reticulum for a cytotoxic effect. Mol Biol Cell (2005) 1.15
Protein C anticoagulant and cytoprotective pathways. Int J Hematol (2012) 1.14
Inhibition of Rab prenylation by statins induces cellular glycosphingolipid remodeling. Glycobiology (2015) 0.77
Activated protein C plasma levels in the fasting and postprandial states among patients with previous unprovoked venous thromboembolism. Thromb Res (2011) 0.75
The cytoprotective protein C pathway. Blood (2006) 5.75
Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med (2003) 4.04
Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med (2007) 3.35
Endothelial and antithrombotic actions of HDL. Circ Res (2006) 2.68
Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med (2004) 2.45
Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron (2004) 2.23
Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med (2006) 2.22
Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J (2003) 1.91
Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest (2009) 1.86
Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood (2004) 1.68
Activated protein C mutant with minimal anticoagulant activity, normal cytoprotective activity, and preservation of thrombin activable fibrinolysis inhibitor-dependent cytoprotective functions. J Biol Chem (2007) 1.67
Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem (2006) 1.58
Pharmacological targeting of the thrombomodulin-activated protein C pathway mitigates radiation toxicity. Nat Med (2012) 1.58
Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci (2011) 1.53
Elevated plasma fibronectin levels associated with venous thromboembolism. Thromb Haemost (2008) 1.49
Activated protein C ligation of ApoER2 (LRP8) causes Dab1-dependent signaling in U937 cells. Proc Natl Acad Sci U S A (2008) 1.45
Effect of hyperhomocysteinemia on protein C activation and activity. Blood (2002) 1.45
Activated protein C targets CD8+ dendritic cells to reduce the mortality of endotoxemia in mice. J Clin Invest (2010) 1.41
Hyperantithrombotic, noncytoprotective Glu149Ala-activated protein C mutant. Blood (2009) 1.36
Retracted Endogenous EPCR/aPC-PAR1 signaling prevents inflammation-induced vascular leakage and lethality. Blood (2009) 1.36
Biased agonism of protease-activated receptor 1 by activated protein C caused by noncanonical cleavage at Arg46. Blood (2012) 1.35
Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J Neurosci (2008) 1.33
High-density lipoprotein deficiency and dyslipoproteinemia associated with venous thrombosis in men. Circulation (2005) 1.31
Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. J Biol Chem (2002) 1.30
Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci (2009) 1.30
Functional recovery after embolic stroke in rodents by activated protein C. Ann Neurol (2005) 1.26
An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke (2012) 1.18
Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes. Blood (2011) 1.17
High-density lipoprotein and the risk of recurrent venous thromboembolism. Circulation (2007) 1.16
Recombinant murine-activated protein C is neuroprotective in a murine ischemic stroke model. Blood Cells Mol Dis (2003) 1.15
Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci U S A (2014) 1.14
Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood (2007) 1.12
Activated protein C preserves functional islet mass after intraportal transplantation: a novel link between endothelial cell activation, thrombosis, inflammation, and islet cell death. Diabetes (2004) 1.11
Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. Thromb Haemost (2009) 1.10
Generation and phenotypic analysis of protein S-deficient mice. Blood (2009) 1.06
Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C. Protein Sci (2002) 1.06
Phase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteers. Curr Pharm Des (2013) 1.03
Cytoprotective-selective activated protein C attenuates Pseudomonas aeruginosa-induced lung injury in mice. Am J Respir Cell Mol Biol (2011) 1.02
An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway. J Neurosci (2013) 1.00
Identification of distinct sequences in human blood coagulation factor Xa and prothrombin essential for substrate and cofactor recognition in the prothrombinase complex. J Biol Chem (2003) 0.99
Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. J Neurochem (2009) 0.99
Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic stroke. Curr Pharm Des (2012) 0.98
A novel ELISA for mouse activated protein C in plasma. J Immunol Methods (2006) 0.97
Species-specific anticoagulant and mitogenic activities of murine protein S. Haematologica (2009) 0.96
Human plasma phospholipid transfer protein specific activity is correlated with HDL size: implications for lipoprotein physiology. Biochim Biophys Acta (2008) 0.95
Organ-specific protection against lipopolysaccharide-induced vascular leak is dependent on the endothelial protein C receptor. Arterioscler Thromb Vasc Biol (2013) 0.93
Protein S confers neuronal protection during ischemic/hypoxic injury in mice. Circulation (2003) 0.93
Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities. Front Biosci (2006) 0.93
Protein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like region. J Neurosci (2010) 0.93
Prothrombin residues 473-487 contribute to factor Va binding in the prothrombinase complex. J Biol Chem (2004) 0.93
Acylideneoxoindoles: a new class of reversible inhibitors of human transglutaminase 2. Bioorg Med Chem Lett (2010) 0.92
Upregulated but insufficient generation of activated protein C is associated with development of multiorgan failure in severe acute pancreatitis. Crit Care (2006) 0.91
Protein C pathway impairment in nonsymptomatic cigarette smokers. Blood Cells Mol Dis (2002) 0.91
Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats. Stroke (2013) 0.91
Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood (2003) 0.89
Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1. Brain Res (2013) 0.89
Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va. Pathophysiol Haemost Thromb (2010) 0.88
Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway. Mol Neurodegener (2011) 0.88
Low protein Z levels and risk of ischemic stroke: differences by diabetic status and gender. Blood Cells Mol Dis (2002) 0.87
Sphingolipids as bioactive regulators of thrombin generation. J Biol Chem (2004) 0.87
The thrombin-sensitive region of protein S mediates phospholipid-dependent interaction with factor Xa. J Biol Chem (2008) 0.87
Characterization of a factor Xa binding site on factor Va near the Arg-506 activated protein C cleavage site. J Biol Chem (2007) 0.86
Failure to validate association of gene polymorphisms in EPCR, PAR-1, FSAP and protein S Tokushima with venous thromboembolism among Californians of European ancestry. Thromb Haemost (2008) 0.85
Cytoprotective-selective activated protein C therapy for ischaemic stroke. Thromb Haemost (2014) 0.84
Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates. Br J Haematol (2006) 0.84
Elevated CETP Lipid Transfer Activity is Associated with the Risk of Venous Thromboembolism. J Atheroscler Thromb (2016) 0.83
Activated protein C-dependent and -independent anticoagulant activities of protein S have different structural requirements. Blood Cells Mol Dis (2002) 0.83
Good or poor responses of hemostatic molecular markers in patients with hematopoietic disorders after treatment of disseminated intravascular coagulation. Clin Appl Thromb Hemost (2003) 0.82
Characterization of a thrombomodulin binding site on protein C and its comparison to an activated protein C binding site for factor Va. Proteins (2004) 0.81
Factor Va increases the affinity of factor Xa for prothrombin: a binding study using a novel photoactivable thiol-specific fluorescent probe. Chem Biol (2002) 0.81
Factor Va residues 311-325 represent an activated protein C binding region. J Biol Chem (2007) 0.81
Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice. Blood Cells Mol Dis (2013) 0.81
Activated protein C reduces graft neutrophil activation in clinical renal transplantation. Am J Transplant (2005) 0.81
Plasma cholesteryl ester transfer protein and blood coagulability. Thromb Haemost (2007) 0.81
Antibody SPC-54 provides acute in vivo blockage of the murine protein C system. Blood Cells Mol Dis (2013) 0.81
Warfarin untargeted metabolomics study identifies novel procoagulant ethanolamide plasma lipids. Br J Haematol (2014) 0.81
Coagulation pathways in atherothrombosis. Trends Cardiovasc Med (2002) 0.80
Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C. Thromb Haemost (2009) 0.80
Infrared fluorescence for vascular barrier breach in vivo--a novel method for quantitation of albumin efflux. Thromb Haemost (2012) 0.80
The apolipoprotein C-I content of very-low-density lipoproteins is associated with fasting triglycerides, postprandial lipemia, and carotid atherosclerosis. J Lipids (2011) 0.79
Activation of protein C during reperfusion in clinical liver transplantation. Transplantation (2003) 0.79
Oral anticoagulation reduces activated protein C less than protein C and other vitamin K-dependent clotting factors. Blood (2002) 0.79
Activated protein C in the cardioplegic solution on a porcine model of coronary ischemia-reperfusion has deleterious hemodynamic effects. Cardiovasc Drugs Ther (2006) 0.78
Identification of new inhibitors of protein kinase R guided by statistical modeling. Bioorg Med Chem Lett (2011) 0.78
Graft protein C entrapment is associated with reduced phagocyte activation during reperfusion in human liver transplantation. Crit Care Med (2006) 0.78
Association of Apo(a)isoform size with dyslipoproteinemia in male venous thrombosis patients. Clin Chim Acta (2010) 0.77
Activation of protein C and hemodynamic recovery after coronary artery bypass surgery. J Thorac Cardiovasc Surg (2007) 0.77
Anticoagulant responses to thrombin are enhanced during regression of atherosclerosis in monkeys. Circulation (2002) 0.77